PURPOSE: The purpose of this work was to evaluate the results of high-dose radiation treatment using carbon ion therapy, alone or combined with intensity-modulated radiation treatment (IMRT), in patients with sacral chordoma. MATERIALS AND METHODS: Between 2009 and 2012, 56 patients with sacral chordoma were treated in our center. The tumor was located above S3 in 33 patients and in S3 or below in 23 patients. In all, 41 patients received radiation therapy for the primary tumor, while 15 patients were treated for the recurrent tumor. Toxicity was measured using NCI CTCAE v.4.03. Local control (LC) and overall survival (OS) were evaluated with the Kaplan-Meier method. RESULTS: A total of 23 patients were irradiated with carbon ions in combination with photon IMRT, while 33 received carbon ion therapy only. Forty-three patients had a macroscopic tumor at treatment start with a median tumor size (GTV) of 244 ml (range 5-1188 ml). The median total dose was 66 Gy (range 60-74 Gy; RBE). After a median follow-up time of 25 months, the 2- and 3-year local control probability was 76 % and 53 %, respectively. The overall survival rate was 100 %. Treatment for primary tumor and male patients resulted in significant better local control. No higher toxicity occurred within the follow-up time. CONCLUSION: High-dose photon/carbon ion beam radiation therapy is safe and, especially for primary sacral chordomas, highly effective. A randomized trial is required to evaluate the role of primary definitive hypofractionated particle therapy compared with surgery with or without adjuvant radiotherapy.
PURPOSE: The purpose of this work was to evaluate the results of high-dose radiation treatment using carbon ion therapy, alone or combined with intensity-modulated radiation treatment (IMRT), in patients with sacral chordoma. MATERIALS AND METHODS: Between 2009 and 2012, 56 patients with sacral chordoma were treated in our center. The tumor was located above S3 in 33 patients and in S3 or below in 23 patients. In all, 41 patients received radiation therapy for the primary tumor, while 15 patients were treated for the recurrent tumor. Toxicity was measured using NCI CTCAE v.4.03. Local control (LC) and overall survival (OS) were evaluated with the Kaplan-Meier method. RESULTS: A total of 23 patients were irradiated with carbon ions in combination with photon IMRT, while 33 received carbon ion therapy only. Forty-three patients had a macroscopic tumor at treatment start with a median tumor size (GTV) of 244 ml (range 5-1188 ml). The median total dose was 66 Gy (range 60-74 Gy; RBE). After a median follow-up time of 25 months, the 2- and 3-year local control probability was 76 % and 53 %, respectively. The overall survival rate was 100 %. Treatment for primary tumor and male patients resulted in significant better local control. No higher toxicity occurred within the follow-up time. CONCLUSION: High-dose photon/carbon ion beam radiation therapy is safe and, especially for primary sacral chordomas, highly effective. A randomized trial is required to evaluate the role of primary definitive hypofractionated particle therapy compared with surgery with or without adjuvant radiotherapy.
Authors: Lily Park; Thomas F Delaney; Norbert J Liebsch; Francis J Hornicek; Saveli Goldberg; Henry Mankin; Andrew E Rosenberg; Daniel I Rosenthal; Herman D Suit Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-06 Impact factor: 7.038
Authors: Daniela Schulz-Ertner; Anna Nikoghosyan; Bernd Didinger; Marc Münter; Oliver Jäkel; Christian P Karger; Juergen Debus Journal: Cancer Date: 2005-07-15 Impact factor: 6.860
Authors: Clinton Devin; Paul Y Chong; Ginger E Holt; Irene Feurer; Adriana Gonzalez; Nipun Merchant; Herbert S Schwartz Journal: J Surg Oncol Date: 2006-09-01 Impact factor: 3.454
Authors: Christopher A Hulen; H Thomas Temple; William P Fox; Andrew A Sama; Barth A Green; Frank J Eismont Journal: J Bone Joint Surg Am Date: 2006-07 Impact factor: 5.284
Authors: Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim Journal: J Bone Joint Surg Am Date: 2005-10 Impact factor: 5.284
Authors: Matthias Uhl; Lutz Edler; Alexandra D Jensen; Gregor Habl; Jan Oelmann; Falk Röder; Oliver Jäckel; Jürgen Debus; Klaus Herfarth Journal: Radiat Oncol Date: 2014-04-29 Impact factor: 3.481
Authors: S Stacchiotti; A Gronchi; P Fossati; T Akiyama; C Alapetite; M Baumann; J Y Blay; S Bolle; S Boriani; P Bruzzi; R Capanna; A Caraceni; R Casadei; V Colia; J Debus; T Delaney; A Desai; P Dileo; S Dijkstra; F Doglietto; A Flanagan; S Froelich; P A Gardner; H Gelderblom; Z L Gokaslan; R Haas; C Heery; N Hindi; P Hohenberger; F Hornicek; R Imai; L Jeys; R L Jones; B Kasper; A Kawai; M Krengli; A Leithner; I Logowska; J Martin Broto; D Mazzatenta; C Morosi; P Nicolai; O J Norum; S Patel; N Penel; P Picci; S Pilotti; S Radaelli; F Ricchini; P Rutkowski; S Scheipl; C Sen; E Tamborini; K A Thornton; B Timmermann; V Torri; P U Tunn; M Uhl; Y Yamada; D C Weber; D Vanel; P P Varga; C L A Vleggeert-Lankamp; P G Casali; J Sommer Journal: Ann Oncol Date: 2017-06-01 Impact factor: 32.976
Authors: Osama Mohamad; Brock J Sishc; Janapriya Saha; Arnold Pompos; Asal Rahimi; Michael D Story; Anthony J Davis; D W Nathan Kim Journal: Cancers (Basel) Date: 2017-06-09 Impact factor: 6.639
Authors: Tilman Bostel; Nils Henrik Nicolay; Thomas Welzel; Thomas Bruckner; Matthias Mattke; Sati Akbaba; Tanja Sprave; Jürgen Debus; Matthias Uhl Journal: Radiat Oncol Date: 2018-08-23 Impact factor: 3.481
Authors: Tamir Ailon; Radmehr Torabi; Charles G Fisher; Laurence D Rhines; Michelle J Clarke; Chetan Bettegowda; Stefano Boriani; Yoshiya J Yamada; Norio Kawahara; Peter P Varga; John H Shin; Arjun Saghal; Ziya L Gokaslan Journal: Spine (Phila Pa 1976) Date: 2016-10-15 Impact factor: 3.241
Authors: Brenton Pennicooke; Ilya Laufer; Arjun Sahgal; Peter P Varga; Ziya L Gokaslan; Mark H Bilsky; Yoshiya J Yamada Journal: Spine (Phila Pa 1976) Date: 2016-10-15 Impact factor: 3.241